233 related articles for article (PubMed ID: 30912222)
1. Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial.
Higuchi T; Iyo M; Kwon JS; Chou YH; Chen HK; Chen JY; Chen TT; Huang SY; Lee JS; Saeki Y; Tanaka H; Wang TS; Wu BJ; Katoh T; Ishigouoka J
Asia Pac Psychiatry; 2019 Sep; 11(3):e12354. PubMed ID: 30912222
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia.
Feng Y; Shi J; Wang L; Zhang X; Tan Y; Zhao J; Ning Y; Xie S; Liu X; Liu Q; Li K; Wang X; Li L; Xu X; Deng W; Luo X; Wang G
Psychiatry Clin Neurosci; 2020 Jun; 74(6):336-343. PubMed ID: 31823444
[TBL] [Abstract][Full Text] [Related]
3. Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study.
Mattingly GW; Haddad PM; Tocco M; Xu J; Phillips D; Pikalov A; Loebel A
BMC Psychiatry; 2020 May; 20(1):199. PubMed ID: 32370778
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.
Goldman R; Loebel A; Cucchiaro J; Deng L; Findling RL
J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):516-525. PubMed ID: 28475373
[TBL] [Abstract][Full Text] [Related]
5. Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients.
Higuchi T; Ishigooka J; Iyo M; Yeh CB; Ebenezer EG; Liang KY; Lee JS; Lee SY; Lin SK; Yoon BH; Nakamura M; Hagi K; Sato T
Asia Pac Psychiatry; 2019 Jun; 11(2):e12352. PubMed ID: 30950208
[TBL] [Abstract][Full Text] [Related]
6. Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study.
Loebel A; Silva R; Goldman R; Watabe K; Cucchiaro J; Citrome L; Kane JM
J Clin Psychiatry; 2016 Dec; 77(12):1672-1680. PubMed ID: 27454547
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of lurasidone in schizophrenia: pooled analysis of European results from double-blind, placebo-controlled 6-week studies.
Calisti F; Cattaneo A; Calabrese M; Mao Y; Tocco M; Pikalov A; Goldman R
Int Clin Psychopharmacol; 2022 Sep; 37(5):215-222. PubMed ID: 35276716
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies.
Costamagna I; Calisti F; Cattaneo A; Hsu J; Tocco M; Pikalov A; Goldman R
Eur Psychiatry; 2021 May; 64(1):e35. PubMed ID: 33966678
[TBL] [Abstract][Full Text] [Related]
10. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study.
Ogasa M; Kimura T; Nakamura M; Guarino J
Psychopharmacology (Berl); 2013 Feb; 225(3):519-30. PubMed ID: 22903391
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta-analysis of phase 3 trials in Japan.
Kishi T; Nosaka T; Sakuma K; Okuya M; Iwata N
Neuropsychopharmacol Rep; 2020 Sep; 40(3):314-322. PubMed ID: 32767739
[TBL] [Abstract][Full Text] [Related]
12. [Effect of Lurasidone on symptoms of schizophrenia in five-factor dimensional model: pooled analysis of two short-term, randomized, double-blind, placebo-controlled studies in patients from Russia and Ukraine].
Mosolov SN; Malyutin AV; Pikalov AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(12):29-37. PubMed ID: 31994511
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies.
Loebel A; Cucchiaro J; Silva R; Mao Y; Xu J; Pikalov A; Marder SR
Eur Psychiatry; 2015 Jan; 30(1):26-31. PubMed ID: 25280429
[TBL] [Abstract][Full Text] [Related]
14. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
Meltzer HY; Cucchiaro J; Silva R; Ogasa M; Phillips D; Xu J; Kalali AH; Schweizer E; Pikalov A; Loebel A
Am J Psychiatry; 2011 Sep; 168(9):957-67. PubMed ID: 21676992
[TBL] [Abstract][Full Text] [Related]
15. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.
Arango C; Ng-Mak D; Finn E; Byrne A; Loebel A
Eur Child Adolesc Psychiatry; 2020 Sep; 29(9):1195-1205. PubMed ID: 31758359
[TBL] [Abstract][Full Text] [Related]
16. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.
Meyer JM; Mao Y; Pikalov A; Cucchiaro J; Loebel A
Int Clin Psychopharmacol; 2015 Nov; 30(6):342-50. PubMed ID: 26196189
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.
Tandon R; Cucchiaro J; Phillips D; Hernandez D; Mao Y; Pikalov A; Loebel A
J Psychopharmacol; 2016 Jan; 30(1):69-77. PubMed ID: 26645209
[TBL] [Abstract][Full Text] [Related]
18. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder.
Potkin SG; Ogasa M; Cucchiaro J; Loebel A
Schizophr Res; 2011 Nov; 132(2-3):101-7. PubMed ID: 21889878
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study.
Citrome L; Cucchiaro J; Sarma K; Phillips D; Silva R; Tsuchiya S; Loebel A
Int Clin Psychopharmacol; 2012 May; 27(3):165-76. PubMed ID: 22395527
[TBL] [Abstract][Full Text] [Related]
20. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
Citrome L
Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
